Fig. 7From: The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activationATOR-1015 improves the effect of anti-PD-1 treatment. Female heterozygous hOX40tg mice inoculated sc with MB49 tumor cells day 0 were treated ip with vehicle, 248 μg ATOR-1015, and/or 250 μg anti-PD-1 (RPM1–14) on days 7, 10 and 13. Tumor volume was measured three times per week. The number of tumor free (TF) mice in each group is indicatedBack to article page